Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225221 · ClinicalTrials.gov registry record · Phase 2
Neurobiology of Bulimia Nervosa
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04225221 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants.
The verdict
NCT04225221, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Leuprolide Acetate
- DRUG Estradiol
- DRUG Micronized progesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225221
The ClinicalTrials.gov registry entry for NCT04225221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Oral Capsule is the first listed.
NCT04225221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04225221 about?
NCT04225221 is a clinical study titled "Neurobiology of Bulimia Nervosa". This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone...
What is the current status of trial NCT04225221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-02-24. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT04225221?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Leuprolide Acetate (DRUG), Estradiol (DRUG), Micronized progesterone (DRUG).
Who is sponsoring clinical trial NCT04225221?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.